Peripheral T-cell lymphoma in childhood and adolescence. A clinicopathologic study of 22 patients.
BACKGROUND
Peripheral T-cell lymphoma (PTCL), although the most common T-cell lymphoma in adults, is relatively rare in childhood, and only small series have been reported.


RESULTS
Twenty-two cases of PTCL were studied that occurred in patients 18 months to 20 years of age. Nine were seen when the condition was diagnosed, and the other 13 were referred after they had relapses. The stage at diagnosis was I or II (45%), III (41%), and IV (14%). Patients with Stage IV disease were younger than those with Stage I or II disease (2.5 versus 14.8 years, P = 0.04). Twelve patients had extranodal disease when the diagnosis was made; the skin was the most common site. Ten tumors were classified as diffuse large cell type; five, as diffuse anaplastic large cell type; and seven, as diffuse mixed cell type. Twenty of the 21 tumors tested were CD30 (Ki-1 or Ber-H2) antigen positive. Of the nine patients seen when the diagnosis was made and treated by the authors, three had a relapse (median, 12 months), a 2-year relapse-free survival (RFS) rate of 61%. For the total group, the RFS was longer for patients older than 12 years of age compared with those who were younger (20 versus 12 months, P = 0.05). Overall, six patients remained in their first complete remission. Sixteen patients had a relapse, and 13 of these underwent bone marrow transplantation (BMT). Six of these remained in complete remission (median, 18 months after BMT). Overall, only 6 of 22 patients died (median survival, > 60 months).


CONCLUSIONS
It was concluded that aggressive therapy, including BMT for relapses, can provide prolonged disease control in most children with PTCL.
Department of Pediatrics, University of Nebraska Medical Center, Omaha 68198-2165.
B G
BG
Gordon
D D
DD
Weisenburger
P I
PI
Warkentin
J
J
Anderson
W G
WG
Sanger
M
M
Bast
D
D
Gnarra
J M
JM
Vose
P J
PJ
Bierman
J O
JO
Armitage
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D015703:Antigens, CD / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D002889:Chromosomes, Human, Pair 2; D002895:Chromosomes, Human, Pair 5; D005260:Female; D006801:Humans; D007223:Infant; D017730:Ki-1 Antigen; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics / Q000276:immunology / Q000401:mortality / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000235:genetics / Q000276:immunology / Q000401:mortality / Q000473:pathology; D016411:Lymphoma, T-Cell, Peripheral / Q000235:genetics / Q000276:immunology / Q000401:mortality / Q000473:pathology*; D008297:Male; D009367:Neoplasm Staging; D012008:Recurrence; D014178:Translocation, Genetic
D015703:Antigens, CD; D000951:Antigens, Neoplasm; D017730:Ki-1 Antigen